Skip to main content
Toggle search
Toggle menu
Enter your keywords
User account menu
Log in
Main navigation
About
History & Impact
Mission & Values
Leadership
Support SWOG
Join SWOG
Policies & Procedures
Careers
Contact Us
The SWOG Network
How We Work
Our Staff
Our Advocates
Our Partners
News & Events
News
SWOG Meetings
For Press
Clinical Trials
Biospecimen Submission
Biospecimen Access
Data Requests
Clinical Trials Search
Clinical Research Resources
Frequently Asked Questions
Publications
Institutions
Quality Assurance & Audits
Serious Adverse Events
Training Resources
CRA Workbench
Protocol Workbench
For Patients
Patient & Advocate Voices
Trials Open to Patients
About SWOG Cancer Trials
Joining a Trial
Main navigation
About
Overview
History & Impact
Mission & Values
Leadership
Support SWOG
Join SWOG
Policies & Procedures
Careers
Contact Us
The SWOG Network
Overview
How We Work
Our Staff
Our Advocates
Our Partners
News & Events
Overview
News
SWOG Meetings
For Press
Clinical Trials
Overview
Biospecimen Submission
Biospecimen Access
Data Requests
Clinical Trials Search
Clinical Research Resources
Frequently Asked Questions
Publications
Institutions
Quality Assurance & Audits
Serious Adverse Events
Training Resources
CRA Workbench
Protocol Workbench
For Patients
Overview
Patient & Advocate Voices
Trials Open to Patients
About SWOG Cancer Trials
Joining a Trial
Main navigation
About
Toggle submenu
History & Impact
Mission & Values
Leadership
Support SWOG
Join SWOG
Policies & Procedures
Careers
Contact Us
The SWOG Network
Toggle submenu
How We Work
Our Staff
Our Advocates
Our Partners
News & Events
Toggle submenu
News
SWOG Meetings
For Press
Clinical Trials
Toggle submenu
Biospecimen Submission
Biospecimen Access
Data Requests
Clinical Trials Search
Clinical Research Resources
Frequently Asked Questions
Publications
Institutions
Quality Assurance & Audits
Serious Adverse Events
Training Resources
CRA Workbench
Protocol Workbench
For Patients
Toggle submenu
Patient & Advocate Voices
Trials Open to Patients
About SWOG Cancer Trials
Joining a Trial
User account menu
Log in
Section navigation
Recent Updates
Toggle menu
5/1/2025
4/15/2025
4/1/2025
3/15/2025
3/1/2025
2/15/2025
2/1/2025
1/15/2025
1/1/2025
12/15/2024
12/1/2024
11/15/2024
All Updates
Breadcrumb
SWOG
Member Resources
Trial & Business Updates
Early Therapeutics & Rare Cancers
Priority List Early Therapeutics & Rare Cancers
CTSU/A071701
II
GENOMICALLY-GUIDED TREATMENT TRIAL IN BRAIN METASTASES
S2012
II-III
Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
S1609
II
DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors
CTSU/A151804
Other
ESTABLISHMENT OF A NATIONAL BIOREPOSITORY TO ADVANCE STUDIES OF IMMUNE-RELATED ADVERSE EVENTS
CTSU/EAY131
Other
Molecular Analysis for Therapy Choice (MATCH)
CTSU/NRG-GY020
III
A Phase III Randomized Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
CTSU/NRG-BR004
III
A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
CTSU/NRG-GY018
III
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
CTSU/A091605
A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma
CTSU/EA3161
II-III
A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA
CTSU/NRG-HN006
II-III
Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer
CTSU/NRG-GY009
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
CTSU/A071401
II
Phase II Trial of SMO/ AKT/ NF2 Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2 Mutations
CTSU/NCICOVID
Other
NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
CTSU/AOST2031
AOST2031: A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma
CTSU/AOST2032
AOST2032: A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
CTSU/NRG-BR004
III
A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer